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Angiogenesis is the process of forming new blood vessel and capillaries from pre-existing vessels. Angiogensis is the 
foundation of reproduction and growth and as well as, responsible for healing of wounds and tissue repair. 
Angiogenesis is a multistep process that involves the induction of angiogenesis by VEGF, destabilization of 
extracellular matrix membranes, sprouting of vessels, migration of cells, and maturation. However angiogenesis is 
also the root of cancer and age related dieseases such as muscular degeneration and several other major cardiovascular 
diseases. There is evidence of various angiogenesis inhibiting therapies that are effective as a treatment method by 
interfering with the development and growth of blood vessels and tumors. This article focuses on the the mechanism 
of angiogenesis and how inhibiting angiogenesis is a crucial step in combatting cancer and disease. The article 
discusses the potential of treatment therapies such monoclonal antibodies and consumption of foods that exhibit anti-
angiogenic properties such as fruits, vegetables, and berries. 
 
INTRODUCTION 
What is the leading cause of death in the U.S.? In 2019, 
the leading cause of death was due to heart disease and 
following behind is cancer according to the National Vital 
Statistics System, Mortality, which remained the same in 
2018. To understand the emergence of cancers and 
diseases, the role of angiogenesis in disease and cancers 
must be understood. 
Angiogenesis is the process of forming new blood vessel 
and capillaries from pre-existing vessels. Cell growth is 
regulated by normal cell division, checkpoints and cell 
signaling. Angiogenesis brings in oxygen and nutrients to 
the body’s tissues allowing for the repair and healing of 
developing or injured tissues. In pathologies, specifically 
cancer, chemical signals and regulations are ignored by 
the cells, and they continue to divide and become 
cancerous. In abnormal angiogenesis, the blood vessel is 
formed by angiogenic stimulators released to the 
surrounding cells of a tumor mass that encourages the 
growth of new blood vessels. In turn, angiogenesis 
supplies the growth and metastasis of cancer cells 
supplying the area with nutrients and creating a perfect 
tumor microenvironment with angiogenic activators that 
are manipulated to create more blood vessels. In 
conclusion, angiogenesis plays both a crucial role in 
health and disease. However, currently knowledge on the 
effects of angiogenesis and angiogenic therapies are 
limited and aren’t widely used. In this paper I review the 
importance of relevant studies that explore a potentially 
exciting treatment using anti angiogenic therapies for 
disease and cancer treatment.  This article will be an 
overview of the promising anti-angiogenic therapies as 
well as the methods and results of studies previously done 
using angiogenesis inhibitors in various diseases such as 
lung cancer and cardiovascular diseases. Without a doubt 
regulating angiogenesis will benefit the advancement of 
treatment in the field of medicine. 
ANGIOGENESIS 
The matrix is a dynamic structure undergoing consistent 
deposition, degradation and modifications of its 
components [1]. There are two types of known 
angiogenesis, sprouting and the intussusceptive splitting 
of preexisting blood vessels; both of which are triggered 
by hypoxic tissues and are not very well understood [2]. 
Sprouting angiogenesis is the formation of new vessels 
from existing blood vessels characterized by the sprouting 
of endothelial cells triggered by VEGFs [2]. Without the 
vascular network, the spread of cancer tissue would not 
proliferate but be hindered in growth due to the lack of 
angiogenesis [3].  
The process of sprouting angiogenesis starts by the 
activation of endothelial cells through growth factor 
molecules or VEGF. VEGF are released by nearby 
hypoxic tumor tissues and will later play an important 
factor in sprouting angiogenesis, as they are sufficient in 
triggering angiogenesis [4]. Endothelial cells are found in 
the inner blood vessels lined by a single cell layer that 
contains VEGF receptors. The expressions of these 
specific receptors are bound by VEGF ligands on the 
blood vessels of endothelial cells triggering a signaling 
cascade  and activates angiogenesis [5]. The binding of 





VEGF to VEGFR releases proteases, which encourages 
the loosening of nearby blood vessel cells. Proteases, 
specifically matrix metalloproteinases (MMPs) have the 
ability to target many proteins, their targets include 
growth factors-binding proteins, cell surface receptors, 
cell-cell, cell adhesion molecules [6]. MMPs are the key 
participant in tip cell functioning and breaking down the 
basement and extracellular matrix (ECM) [7].  The ECM 
is present in all cells and consists of various components 
of different signaling molecules that are secreted from 
mesenchymal cells that are important for development. 
The loosening of the vessel cell allows for the sprouting 
mechanism that forms an extension of endothelial cells as 
a new vessel grow towards an angiogenic stimulus 
VEGF-A [2]. As the capillary sprout emerges from 
endothelial cells that will elongate, it extends the 
filopodia and explores the microenvironment becoming 
tip and stalk cells.  
The mechanisms of notch signaling pathways and VEGFs 
enforce a cascade that continuously re-evaluates with the 
aid of many other signaling pathways that participate in 
the regulation of specializing into tip cells [8]. 
Morphically, the tip cells will soon be joined cell to cell 
by the merging of the vacuoles, which creates a uniform 
lumen shared by many cells but a separated cytoplasm. 
Tip cells contain receptors and exhibit migratory behavior 
in endothelial cells during sprouting angiogenesis and 
they sense the environment for guidance cues. The tip cell 
expresses Netrin receptor uncoordinated-5B (UNC5B) 
and Neuropilin (NRP), which will help detect attractive 
signals from the tissue microenvironment and then follow 
into a multistep processes of adhesion and detachment, 
and leading to directed migration [7]. 
 The tip cells form filopodia and lamellipodia which are 
involved in cell migration. Filopodia are plasma 
membranes that contain bundles of actin filament that aids 
in the tip cells to probing their environment [7]. 
Lamellipodia are thin fan-like projections that are found 
in the leading edge of many moving cells, such as 
endothelial tip cells [9]. Lamellipodia are regarded as the 
major driving force of mesenchymal cell migration in 
both normal and disease-causing environments [10]. The 
movements of cell migration are in the protrusion of the 
leading edge, adhesion of the leading edge, de-adhesion 
of the trailing edge, and then movement of the cell body 
[11]. The mechanism starts with determining the direction 
of the cell body, and then the cell extends a protrusion in 
the direction of the movement via actin polymerization in 
the leading edge. The cell then adheres the leading end to 
the surface in the direction in which it is moving then de-
adheres the cell body from the rear [11]. On the contrary, 
stalk cells are endothelial and proliferative but do not 
form filopodia and follow behind tip cells [8]. Stalk cells 
form the body and elongate as the sprouting occurs [12]. 
However, it has been found that previously inhibited stalk 
cells can be relieved from their inhibition and then 
become tip cells [8]. In other words, tip-stalks do not 
exhibit a fixed cell fate but instead, a dynamically 
exchangeable phenotype specification fluctuation [8].   
The uniform lumen will provide direct supply of oxygen 
and glucose to the hypoxic tissue, providing a perfect 
microenvironment. When the tissue flourishes because of 
the oxygen it will increase in size, further develop, and 
possibly exhibit more harm by metastasis. If the tumor 
metastasis occurs, the tumor will travel to new places in 
the body through blood vessels and capillaries in search 
for a new environment to grow. In essence, the blood 
vessels provide a route by which tumor cells exit the 
tumor site and enter circulation [13]. Overall, tip cells and 
stalk cells work together to form a vascular sprout that 
grows towards the VEGR in response to the chemical, 
mechanical factors, and some degree of random motility 
[14].  
Intussusceptive Angiogenesis is the lesser understood 
angiogenesis method discovered after sprouting 
angiogenesis, yet it is faster and lacks dependence on 
endothelial cell proliferation for growth. The major 
difference between this two angiogenesis’ is the presence 
of pillars in the intussusceptive method, which are made 
of connective tissue called tissue pillars, and inserted into 
the lumen resulting in division of the lumen and an 
increase in the density of the capillary network [15]. 
Sprouting and intussusceptive angiogenesis are both 
critical to processes involving wound healing and 
embryonic development. However over 70 diseases, such 
as cancer and occlusive vascular disease relay on 
angiogenesis for development and proliferation [16].  
Angiogenesis plays such a huge role in disease and 
illness, theocratically inhibiting angiogenesis could 
prevent a lot of diseases and illnesses, since without these 
factors (oxygen and nutrients) they wouldn’t adequately 
meet the requirements to promote angiogenesis. Tumors 
that grow bigger than a few millimeters will need oxygen 
and nutrients in order to enlarge. Similarly, diseases like 
cancer will need oxygen and nutrients in order to invade 
nearby tissues and metastases, without it the cancer will 
remain in a dormant state. In another relevant study done, 
a region that lacked blood circulation the tumors grew to 
a size of approximately 1-2mm3 before they halted. 
Unfortunately, it was found that these tumors grew 
beyond 2mm3 when placed in an area with angiogenic 
support [17]. Therefore, if oxygen and nutrients are 
inhibited from nourishing pathological tissues including 
hypoxia, and the biochemical and physiologic pathways 
that facilitate development of these tissues are altered and 
intercepted in some way, then some diseases and illnesses 
will not be successful in the development malignancy. 





Angiogenesis inhibitors express anti-angiogenesis 
activity, while the tumor angiogenic switch seems to be 
activated when the balance shifts from angiogenic 
inhibitors to angiogenic stimulators [18]. Angiogenesis 
inhibitors work by blocking the growth of the blood 
vessels that support the tumor development rather than 
inhibiting the growth of the tumor tissues. 
MOLECULAR MEDIATORS IN ANGIOGENESIS 
There are many molecular mediators that play a part in 
angiogenesis. The vascular endothelial growth factor 
(VEGF) is one of the most crucial molecular mediators in 
the development of new blood vessels from existing blood 
vessels. These molecular mediators that aid angiogenesis 
keep the body healthy. Other growth factors that are a part 
of the formation of new blood vessels like VEGF include 
fibroblasts growth factor (FGF), tumor necrosis factor-
alpha (TNF- α), transforming growth factor (TGF-β), and 
the angiopoietins (Ang) [19]. Expression of VEGF is 
fundamental as it has an extensive range of functions and 
acts jointly on many varieties of cell types, in essence 
allowing for homeostasis in the human body. The ligands 
of the VEGF family include VEGF-A, VEGF-B, VEGF-
C and VEGF-D and bind to VEGF receptors such as 
VEGFR1, VEGFR2 and VEGFR3. VEGF plays a role in 
the physiological processes of development that supply 
blood and oxygen to cells through a series of vessels, 
which allows for wound healing and increasing blood 
flow to an area [20].  The ligand VEGF-A/receptor 
VEGFR-2 signaling appears to be more frequent and 
distinguished as the predominant mediator involved in the 
angiogenesis pathway [14]. Increasing blood flow and 
angiogenesis can benefit certain health related problems 
like heart disease, arterial disease, and promote wound 
healing.  Other physiological processes that are associated 
with upregulation of VEGF/VEGFR- system  include 
VEGF being widely expressed during the female 
reproductive cycle, reproductive cycle, as well as bone 
repair [21]. 
On the other hand, increased angiogenesis is non-
therapeutic and harmful in the case of tumor development 
and growth, sepsis, arthritis and other diseases. Tumor 
angiogenesis is stimulated by VEGF through several 
mechanisms, including enhancing endothelial cell 
proliferation and survival; increased migration through 
the formation of lattice network and invasion of 
endothelial cells; and enhancing chemotaxis [22]. 
Therefore, it has been concluded that inhibiting VEGF 
would interrupt the growth of tumors as it plays such a 
vital role in the formation of blood vessels. Inhibition of 
VEGF signaling with anti-VEGF strategies were designed 
to target abnormal angiogenic production and used in 
anticancer therapy. Many molecules and proteins such as 
small molecules (kinase inhibitors), peptides, antibodies 
and aptamers play a critical role in the body in the 
formation of complex macromolecules and 
immunological protection from intrinsic and extrinsic 
factors. These important agents create essential building 
blocks that allow for the healthy functioning of the body. 
Interestingly enough, it has been confirmed that using 
these agents and combination of other treatments, have 
the potential to work against and block VEGF and be used 
as a treatment in cancer patients. Cancers lacking 
angiogenesis will remain latent and tumors do not grow if 
blood isn't supplied which is why angiogenesis is an 
important topic in medicine. In clinical trial patients with 
lower levels of VEGF expression, survival was 
significantly greater than patients with higher levels of 
VEGF expression found in the body. The first FDA 
inhibiting angiogenesis target therapy drug, bevacizumab 
was officially approved in patients with metastatic 
colorectal cancer, metastatic breast cancer, lung cancer, 
renal cell carcinomas and glioblastoma multiforme [23]. 
ANGIOGENESIS INHIBITORS 
There are various therapies including angiogenesis 
inhibitors being used as a treatment method by interfering 
with development and growth. Monoclonal antibodies are 
laboratory made molecules that act as a human antibody 
protecting our immune system by mimicking natural 
immune system functions. Monoclonal antibodies are one 
of the most significant strategies for treatment of cancer 
and other diseases. Examples of some monoclonal 
antibodies that act as angiogenesis inhibitors are 
Bevacizumab (Avastin), Aflibercept (Zaltrap) and 
Ramucirumab (Cryramza) [24]. These monoclonal 
antibodies work by targeting VEGF and VEGFR in the 
body.  
Bevacizumab (Avastin) is a recombinant humanized 
immunoglobulin G (IgG) monoclonal antibody that 
targets VEGF-A and inhibits formation of the VEGF-A 
and VEGFR-2 complex [24, 25]. In 2004, US FDA 
approved Bevacizumab for treatment of metastatic 
colorectal cancer with a combination of chemotherapy 
[26]. Currently Bevacizumab is used on patients with 
various cancers, metastatic renal cell carcinoma, breast 
cancer, epithelial ovarian cancer, glioblastoma [24, 27-
31]. As a result of successful clinical validation in patients 
who had taken bevacizumab to as act the specific inhibitor 
of VEGF-A/VEGFR2 interactions, there has been an 
increase of monoclonal antibody development to target 
VEGFR2 since it showed promising results for anti-
angiogenesis [24]. 
Aflibercept (Zaltrap) is another monoclonal antibody that 
suppresses tumor angiogenesis by tricking VEGF-A, 
VEGF-B and PIGF [24]. In 2012, the FDA approved 
aflibercept to be used as a treatment on patients with 
resistant and progressive metastatic colorectal cancer 





[32]. The FDA also approved aflibercept (Eylea) to be 
used as treatment on patients with wet age-related 
muscular degeneration, which is responsible for one most 
common cause of blindness in the elderly [32, 33]. 
Ramucirumab (Cyramza) is a monoclonal antibody that 
targets VEGFR-2 and is used in combination with 
paclitaxel to treat patients with advanced 
gastroesophageal cancer and have progressed after initial 
treatment [34]. It was approved by the FDA for non-small 
cell lung cancer patients, results from phase 3 of clinical 
trial showed promising results and even greater benefit for 
patients with aggressive tumor behavior of this antibody, 
however it has been found that Ramucirumab can cause 
severe toxicity in patients [35]. Other treatment therapies 
include consumption of foods that exhibit anti-
angiogenesis properties. For example, these include 
fruits, vegetables, berries, parsley, and green tea. 
GREEN TEA ANTI-INFLAMMATORY AND ANTI-
CANCER PROPERTIES 
The consumption of tea, specifically green tea, has been 
shown to inhibit the growth of angiogenesis. Green tea 
comes from dried tea plants of the Camellia sinensis 
family. Green tea has many benefits for the body, besides 
being rich in antioxidants research has found that drinking 
green tea may promote the prevention of disease. 
Polyphenols are the chemicals found in green tea that 
have antioxidant potential and are classified as catechins. 
Researchers have found that the extract of green tea 
contains high amount catechins that reveal anti-
tumorigenic activity and anti-inflammatory capabilities 
[36]. Recent scientific research suggests that catechins 
exhibits efficient prevention of lung cancer, liver cancer, 
esophageal cancer, and prostate cancer [37]. Another 
research suggests that green tea consumption improves 
circulation and promotes vessel dilation which can be a 
preventive measure in chronic smokers from 
cardiovascular related diseases [38]. Overall catechins 
found in green tea have exhibited anti-carcinogenic, 
antimutagenic, anti-inflammatory mechanisms [39]. This 
is the reason why green tea has been heavily focused on 
as an anti-cancer and anti-inflammatory preventative. 
GREEN TEA AND NSAIDS COMBINATION 
SYNERGISTIC ANTI-CANCER EFFECTS 
In a study done in Japan in 1983, at the National Cancer 
Center Research Institute in Tokyo and Saitama Cancer 
Center Research Institute they have found that the main 
catechins found in green tea includes 10-15% of 
epigallocatechin gallate (EGCG), 6% to 10% 
epigallocatechin (EGC), 2% to 3% epicatechin gallate 
(ECG), and 2% epicatechin (EC) [40]. Out of the main 
catechins found, EGCG is the most abundant and active 
catechin found in green tea followed by EGC and ECG, it 
has been found that all of the catechin exhibit cancer 
preventive activity besides EC. It appears to be an inactive 
tea catechin and does not reveal effective anticancer 
activity, however when EC is combined with EGCG as a 
treatment it showed synergistic effects on apoptosis 
performance [41]. Many studies have been done on 
rodents targeting many organs with EGCG, the results 
reported that EGCG and green tea catechins can have 
systemic effects on cells towards anticariogenic activity 
[42]. Consuming a certain amount of green tea per day has 
seen a potentially preventative effect on lung , colorectal, 
liver and stomach [43, 44] and breast cancer [45]. In 
patients with breast cancer, it has shown that EGCG 
interfered with the function of estrogen receptors, 
inhibited cell proliferation of estrogen-induced breast 
cancer and increased the sensitivity of the tumor to drugs 
that target steroid receptors [46-48].  
The outcome and success level of using EGCG as an anti-
malignant and repressor of cancer differs in different 
types of cancer and per individual. It has been found that 
a combination of EGCG and nonsteroidal anti-
inflammatory drugs (NSAIDs), like sulindac, acting 
synergistically for enhanced anticancer activity while 
treatment with either EGCG or sulindac alone have only 
a minor effect on promoting anticancer activity [49]. In 
conclusion when EGCG and green tea catechins are used 
in combination with other anticancer compounds, 
repression of tumor growth and anticancer effects 
increased in various human cancer cells [40]. 
SUBJECT AND METHODS 
Angiogenesis inhibition in cancer prevention as a result 
of drinking green tea is significant because it’s 
inexpensive, easily accessible, and not very time 
consuming. Drinking green tea daily can lower your risk 
of contracting cancer and improve your overall health. 
The antioxidants in green tea such as catechins inhibit 
angiogenesis naturally without the aid of medication. This 
is extremely relevant in today’s society as many people 
are heavily reliant on medication and never have enough 
free time to worry about their personal health. This study 
focused on the preventative effects of the consumption of 
green tea and the significance of green tea in the 
prevention of and to decrease the risk of cancer and 
disease, like cardiovascular diseases, which are often 
observed in patients with lung cancer [44]. The study was 
done in 1986 in Saitama, Japan in residents over the age 
of 40 of 8,552 individuals. They first initiated this study 
by conducting a questionnaire covering 90 lifestyle 
factors, and then organized the results. From 1986 to 
1997, a timespan of 11 years, there were a total of 488 
cancer cases. They organized the results on green tea 
consumption in these categories, below 3,4-9 and over 10 
cups a day on these cancer patients. They had found the 





most common cancer in both sexes, in order, were cancers 
of the stomach, lung, colon, rectum and liver [44]. 
RESULTS 
It was concluded among women who had high 
consumption of green tea, consuming over 10 cups a day 
had the most significant decrease in cancer by as much as 
40%. Although, all categories of women who drank below 
3 or 4-9 cups a day all show decreased signs of cancer 
[44]. Interesting enough, the results between women and 
men were opposite for those consuming over 10 cups a 
day. Among men who had high consumption of green tea, 
consuming over 10 cups a day suggested an increased rate 
of cancer incidence [44]. The reasoning for the increased 
cancer incidence in men when consuming over 10 cups of 
tea a day, was that those who were consuming the greatest 
amount of tea also had increased cigarette consumption. 
This was deemed true, as the results revealed that among 
men who never smoke and those who quit smoking both 
showed a decrease in cancer incidence with a higher 
amount of green tea consumption daily [44]. In both male 
and female, it showed a correlation and association of 
decrease in cancer incidence in those who were 
nonsmokers and those who quit smoking with 
consumption of over 10 cups of tea daily. Those 
consuming below 3, 4-9 and over 10 cups a day showed 
an exponential decrease in cancer incidences [44]. 
Proceeding, the team studied the effect of green tea based 
on the type of cancer. For example, consumption of a high 
amount of green tea daily had the greatest impact for 
individuals who had lung cancer in both males and 
females [29]. In conclusion the study showed that green 
tea exhibits some preventative effects of cancer, 
specifically lung cancer and decreased incidences of 
cancer for those consuming over 10 cups a day without 
tobacco use. 
CONCLUSION 
Cancer and disease are the leading causes of death in the 
United States every year. Angiogenesis has shown to 
exhibit a role in disease and health as it is the main 
mediator in healing as well as the proliferation of tumors 
and malignant diseases. While angiogenesis is a natural 
process that takes place in the course of life development, 
it ultimately exacerbates tumor growth in cancer patients. 
VEGF and VEGFR signal angiogenesis and play a crucial 
role in healing and the development of diseases; it is 
advantageous in cases with heart disease and arterial 
disease, but disadvantageous to individuals with lung and 
breast cancer. Treatment therapies targeting VEGF and 
VEGFR in the body include the consumption of foods that 
exhibit anti-angiogenic properties. For example, 
vegetables, berries, parsley and specifically green tea. 
Monoclonal antibodies have been developed targeting 
VEGF and VEGFR, these antibodies include 
Bevacizumab (Avastin), Aflibercept (Zaltrap) and 
Ramucirumab (Cryramza). Green tea contains a high 
content of EGCG, which has been found to inhibit 
angiogenesis through cell proliferation, apoptosis, and 
inhibition of angiogenesis expression. Particularly, this 
paper discussed the cohort study on the effect of green tea 
on disease prevention and the correlation of the decrease 
in cancer incidences in individuals who consumed a high 
amount of green tea daily. Green tea exhibits a 
preventative effect in cancer, specifically lung cancer and 
decreases the incidences of cancer for those consuming 
over 10 cups a day.  
To conclude, angiogenesis has a major role in both 
healing and the development of diseases, many 
monoclonal antibodies have been developed to inhibit 
angiogenesis and the efficacy varies depending on the 
type of cancer. For a natural route, foods that contain 
EGCG, for example in fruits, vegetables, berries, parsley, 
and specifically green tea have shown a preventative 
effect on cancer. 
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